SEC Form 4 · accession 0001553878-17-000013
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Mason
Officer — VP, Finance and Treasurer
Period of report
May 16, 2017
Accepted (ET)
May 17, 2017 · 6:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 16, 2017 | M | 5,625 | $18.66 | A | 5,625 | D | |
| Common Stock | May 16, 2017 | M | 3,750 | $7.10 | A | 9,375 | D | |
| Common Stock | May 16, 2017 | S | 9,375 | $70.00 | D | 0 | D | |
| Common StockF2 | holding | — | — | — | 2,176 | I | By Managed Account |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $7.10 | May 16, 2017 | M | 3,750 | D | — | Nov 30, 2021 | Common Stock | 3,750 | 0 | D |
| Stock Option (Right to Buy)F3 | $18.66 | May 16, 2017 | M | 5,625 | D | — | Dec 20, 2022 | Common Stock | 5,625 | 0 | D |
Explanation of responses
- F1All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2016.
- F2The reporting person owns 2,176 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- F3The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.